InvestorsHub Logo
Followers 49
Posts 5065
Boards Moderated 0
Alias Born 03/23/2014

Re: Sojourner55 post# 76053

Saturday, 09/24/2016 6:48:33 PM

Saturday, September 24, 2016 6:48:33 PM

Post# of 691679
Sojourner55, you wrote:

This says it all.
"We believe the broad applicability of DCVax to many cancers provides multiple opportunities for commercialization and partnering. "
"We believe that mobilizing all agents of the immune system, and targeting all biomarkers on the patient’s cancer, contributes to the effectiveness of DCVax."
Keep your eye on the ball. The rest is just noise.


Well, the above 2 statements are indeed "encouraging"; however: NWBO has been making these statements for a long time .... and it has become obvious over the past several years that the above 2 issues is "not all that counts".
Since there are so many other issues that count as well. Dilution, MFN clause, shorts, wolfpack, cash flow, lack of regular stockholder updates, basher articles, interpretation of early trial results, internal controls, investigation, phase V report, violation of 1 share price rule, delays, HE uncertainty, EAMS uncertainty, lack of updates regarding Sawston (and its remediation) etc etc.
So my point is ... there are many issues that count, and the above 2 issues do not tell the whole story nor "say it all".
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News